ArticleVirology journal2025
Human papillomavirus prevalence and genotype distribution among 30,147 screened women and 3,362 cervical cancer patients in China: a retrospective study.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pathogenic Mechanisms in Cervical Cancer: Energy Metabolism, Hypoxia and Therapy.Life (Basel, Switzerland) · 2026Review
- Genotoxic Bacteria and Oncogenic Viruses in Colorectal Cancer: Evidence, Gaps, and a Proposed Interaction Model.International journal of molecular sciences · 2026Review
- Diagnostic utility and tissue localization of HPV16 and HPV18 E7 immunohistochemistry in cervical lesion progression: a comparative study with PCR.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPersistent infection with high-risk human papillomavirus (HR-HPV) is the primary cause of cervical cancer. Understanding genotype distribution and evaluating screening strategies are essential for effective prevention.
methodsWe retrospectively analyzed cervical cancer screening data from 97,686 women aged 35-64 years in Nanjing (2021-2023). Among these, 30,147 underwent combined cytology and HPV testing and 67,539 TCT alone. HPV genotyping was further performed in 3,362 histologically confirmed cervical cancer cases (3,014 squamous cell carcinomas [SCC] and 348 adenocarcinomas [ADC]) from multiple regions in China.
resultsCombined screening achieved a significantly higher detection rate of abnormalities than TCT alone (13.70% vs. 1.79%, p < 0.001). Overall HPV positivity was 11.19%, increasing with age and peaking at 16.85% in women aged 60-64. The most frequent genotypes were HPV52, HPV58, and HPV16. In cervical cancer cases, HPV was detected in 92.73% of SCC and 59.77% of ADC. The proportion of HPV-negative cancers increased with age, particularly in ADC.
conclusionsCombined TCT and HPV testing improves detection of cervical lesions compared with cytology alone. The observed age-specific and histology-specific differences in HPV prevalence and genotype distribution emphasize the need for tailored screening strategies, particularly for older women. These findings provide region-specific evidence to support the refinement of cervical cancer prevention and control strategies in China, particularly in contexts with similar demographic and epidemiological characteristics to the study population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.